Amy M. Moskop

Oncology

8915 W Connell Ave
Milwaukee, WI 53226

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.

Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.

Journal: Transplantation and cellular therapy

Published: April 01, 2026

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

Journal: Blood advances

Published: March 24, 2026

Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.

Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 25, 2026

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Journal: Transplantation and cellular therapy

Published: February 12, 2026

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: January 14, 2026

Donor selection, graft engineering, and dosing oh my!

Donor selection, graft engineering, and dosing oh my!

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377.

Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377.

Journal: Transplantation and cellular therapy

Published: September 30, 2025

Congenital Myelodysplastic Syndrome in a Newborn With Germline JAK2 Variant Treated With Liposomal Cytarabine-Daunorubicin and Allogeneic Hematopoietic Stem Cell Transplant.

Congenital Myelodysplastic Syndrome in a Newborn With Germline JAK2 Variant Treated With Liposomal Cytarabine-Daunorubicin and Allogeneic Hematopoietic Stem Cell Transplant.

Journal: Pediatric blood & cancer

Published: August 29, 2025

Statistical Methods for Chimeric Antigen Receptor Cell Therapy Outcomes: A Review and Practical Considerations.

Statistical Methods for Chimeric Antigen Receptor Cell Therapy Outcomes: A Review and Practical Considerations.

Journal: Transplantation and cellular therapy

Published: August 09, 2025

Statistical Methods for CAR-T cell Therapy Outcomes: A Review and Practical Considerations.

Statistical Methods for CAR-T cell Therapy Outcomes: A Review and Practical Considerations.

Journal: Transplantation and cellular therapy

Published: August 09, 2025

Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR.

Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR.

Journal: Transplantation and cellular therapy

Published: May 14, 2025

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Journal: Blood advances

Published: April 29, 2025

Showing 1-12 of 41

Last Updated: 09/26/2026